Compound reference
BPC-157 Dosage Guide 2026: The Research vs Reported Use
Short answer
What it is: BPC-157 is a synthetic pentadecapeptide, a 15-amino-acid peptide built from a fragment of a human gastric protein, studied almost entirely in rodents.
The trial doses: there are none. No completed human randomized trial exists as of July 2026, and no validated human dosing regimen exists either; the published rodent work ran 10 micrograms, 10 nanograms, and 10 picograms per kilogram.
The headline number: every human exposure in the published record adds up to 30 analyzed subjects across three uncontrolled pilot studies, 31 enrolled in total.
The catch: the internet dose exists anyway. Community posts cluster around 250 to 500 micrograms a day, with no trial behind any of it.
Why it trips people: posts quote micrograms, vials come in 5mg and 10mg, and syringes read in units.
The status: not FDA approved as of July 2026, and FDA lists it as a compounding safety risk. The evidence is almost entirely preclinical, and this page leads with that.
The calculator
How it works: enter a vial size, a water amount, a syringe type, and a dose. It returns the concentration, the volume, and the reading in units on the barrel.
Units converter
Converts the numbers you type. It does not recommend a dose.
Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.
The Decadewise briefing
One compound, one paper, or one piece of math like this, every week. Free.
Education only. Unsubscribe anytime.
On this page
Community reports, not a protocol
What do users report running?
The background: no completed randomized human trial exists, so every number below comes from community pages and protocol blogs. Not from research.
The cluster: posts converge on 250 to 500 micrograms a day, usually described as a once-daily subcutaneous injection.
The vials: 5mg and 10mg are the sizes these posts are written around.
The cycles: on and off blocks show up repeatedly, most often described as several weeks on followed by a break.
The stack: TB-500 is the compound most often named alongside BPC-157 in the same posts.
The folklore: many posts describe injecting near the injury. The published work used other routes: intraperitoneal in the rat studies, intra-articular in the one human chart review.
None of it verified: no control groups, no dose verification, no outcome measurement. This is a record of what people say they do, not evidence of what BPC-157 does.
Why it's here: anyone searching for a BPC-157 dose will meet these numbers anyway. Seeing them labeled correctly beats pretending they came out of a trial.
Peer-reviewed research
What does the research show?
The headline: no completed human randomized trial exists for BPC-157 as of July 2026. No approved formulation, no validated dosing regimen, no completed phase 2 trial (Mateescu et al., Pharmaceutics, 2026).
The human record: every published human exposure adds up to 30 analyzed subjects across three uncontrolled pilot studies: 16 analyzed for intra-articular knee pain, 12 in the interstitial cystitis pilot, and 2 in the intravenous safety and pharmacokinetics pilot (Lee and colleagues, 2021 to 2025).
The best-known human paper: a 2021 retrospective chart review of knee pain injections (Lee and Padgett). Sixteen of 17 patients were reached by phone, and 11 of the 12 who received BPC-157 alone reported significant improvement.
The fine print: no control group and no standardized tools to measure improvement. The authors themselves said future studies are needed.
| Study | Design | People | What it found |
|---|---|---|---|
| knee pain injections, 2021 | retrospective chart review, no control group | 16 of 17 followed up | 87.5% reported relief; no standardized outcome tools |
| interstitial cystitis pilot | uncontrolled pilot, 12 women | part of 30 analyzed total | no adverse effects reported |
| IV safety and pharmacokinetics pilot | uncontrolled pilot, 2 participants | part of 30 analyzed total | no adverse effects reported |
| hamstring strain, NCT07437547 | randomized, placebo-controlled phase 2 | 120 planned | recruiting since February 2026; no results yet |
The rodent record: this is where the volume lives. The classic study (Staresinic et al., Journal of Orthopaedic Research, 2003) transected the Achilles tendon in rats, then gave BPC-157 at 10 micrograms, 10 nanograms, or 10 picograms per kilogram, once daily, and reported improved healing across biomechanical, functional, microscopic, and macroscopic measures.
The pattern: an independent review (Gwyer et al., Cell and Tissue Research, 2019) found consistently positive and prompt healing effects across injury types, then stated the caveat that matters: the majority of it is small rodent work, and efficacy is yet to be confirmed in humans.
The concentration problem: only a handful of research groups have run the in-depth studies (Gwyer et al., 2019). The two animal papers cited here come from the same Zagreb pharmacology group.
The time capsule: the 2003 paper describes BPC-157 as currently in clinical trials for inflammatory bowel disease. Two decades on, the published human record is still those three pilots.
The pharmacology wrinkle: plasma half-life runs under 30 minutes, with intramuscular bioavailability of 14 to 51 percent depending on species, yet reported effects last hours to days (Mateescu et al., 2026). The review calls that disconnect a direct problem for dosing strategy.
The stability quirk: BPC-157 is unusually stable in gastric juice, and the preclinical work showed activity by oral, parenteral, and topical routes (Mateescu et al., 2026).
One trial is finally running: a randomized, double-blind, placebo-controlled phase 2 in acute hamstring strain started recruiting in February 2026, planning 120 participants, with estimated completion in 2028 (ClinicalTrials.gov, NCT07437547). Until it reads out, the honest answer to every dosing question below is that the research does not have one.
0
completed human randomized trials, as of July 2026
3
uncontrolled human pilot studies, 30 subjects analyzed
10mcg/kg
top of the published rodent dose range; effects also reported at 10pg/kg
200+
papers indexed on PubMed, almost entirely preclinical
Mateescu et al., Pharmaceutics 2026; Staresinic et al., J Orthop Res 2003; PubMed count pulled 19 July 2026.
Does the research match the internet dose?
The tension: the research has no human dose, and the internet has one anyway. Most pages resolve that by simply handing out a schedule; we are doing neither.
What the research can support
What it is for: the rodent studies exist to test whether the peptide does anything at all, across doses from picograms to micrograms per kilogram. They were never designed to set a human schedule.
What it is: a signal worth a real trial, which is finally running. Not a dosing recommendation.
What the posts show
The pattern reported: 250 to 500 micrograms a day, subcutaneous, in on-and-off cycles, often alongside TB-500. None of it comes out of a controlled setting.
Where it comes from: community convention, not a validated method. No published study has ever derived a human dose from the rodent work.
Which of those numbers belongs to you is not our call to make.
The real question: what it comes down to is your body, your risk tolerance, and a doctor who knows your history. What we can give you is what the studies measured and the math behind a dose; the rest is yours to weigh with someone qualified.
How does the units math work?
The point: the math, once, in general terms, attached to nobody's dose.
Example one: say a 5mg vial gets reconstituted with 2mL of bacteriostatic water. That's 2.5mg per mL, or 2500mcg per mL.
The syringe side: a U-100 insulin syringe holds 100 units to the mL, so each unit is 1/100th of a mL, which at this concentration is 25mcg, or 0.025mg. From there: 250mcg is 10 units, 500mcg is 20 units.
Change one thing: reconstitute the same 5mg vial with 1mL instead of 2mL. Concentration doubles to 5mg per mL.
What changes: each unit now equals 50mcg instead of 25mcg. The same 250mcg amount is now 5 units, not 10.
The 10mg vial: a 10mg vial with 2mL lands at the same 5000mcg per mL, so its unit counts match the second row, not the first.
The forum trap: that "10 units" someone read on a forum could be 250mcg at one concentration and 500mcg at another.
| Water added | Concentration | 1 unit equals | What the article works out |
|---|---|---|---|
| 2mL | 2.5mg per mL (2500mcg per mL) | 25mcg (0.025mg) | 250mcg is 10 units, 500mcg is 20 units |
| 1mL | 5mg per mL (5000mcg per mL) | 50mcg | 250mcg is 5 units, 500mcg is 10 units |
| Syringe | Units per mL | 1 unit equals |
|---|---|---|
| U-100 | 100 units per mL | 0.01mL |
| U-40 | 40 units per mL | 0.025mL |
The other trap: your syringe. It reads in units at two scales, independent of concentration.
The two scales: U-100 runs 100 units per mL, one unit is 0.01mL. U-40 runs 40 units per mL, one unit is 0.025mL.
The 2.5x problem: use a U-40 while counting in U-100 units and every unit is 2.5 times the volume you expect. Same vial, same concentration, same "10 units" on the barrel.
First check which syringe you are actually holding; the math depends on it.
Both halves: that's the whole units-versus-micrograms confusion, both halves of it. The barrel is never wrong. It also never knows your concentration or its own scale; that is on you.
How many units is 500mcg of BPC-157?
The short answer: it depends on the concentration. At 2500mcg per mL (a 5mg vial plus 2mL of water), 500mcg reads as 20 units on a U-100 syringe. At 5000mcg per mL (a 5mg vial plus 1mL, or a 10mg vial plus 2mL), 500mcg reads as 10 units.
The rule: no microgram amount maps to one units number universally. Concentration first, syringe type second, then the arithmetic, or run the numbers above.
What's not known yet?
The status: BPC-157 is not approved for human clinical use by any regulatory authority. Not FDA approved as of July 2026.
The compounding line: FDA listed BPC-157 among the bulk substances that may present significant safety risks in compounding, citing immunogenicity risk, impurity concerns, and insufficient information to judge harm. The nomination was withdrawn in 2026, and BPC-157 is back on the July 23 to 24, 2026 advisory agenda for an ulcerative colitis use (fda.gov, checked 20 July 2026).
The sports line: WADA prohibits it outright under S0, the catch-all category for unapproved substances (USADA, checked 19 July 2026).
The one live trial: the first randomized, placebo-controlled phase 2 (hamstring strain, 120 planned, NCT07437547) started recruiting in February 2026, with completion estimated for 2028. Until it reads out, "no completed randomized human trial" stands.
The real gaps:
- No validated human dosing regimen, at any dose, for any condition.
- No characterized human pharmacokinetics beyond a two-subject pilot; the half-life figure comes from animal work.
- No verified data on the community patterns that dominate online discussion: the 250 to 500 microgram days, the cycles, the TB-500 stacks. None of it has been studied in any controlled trial.
Any source claiming otherwise is guessing.
The biggest gap: in our read, one gap towers over any dose number. A research-grade vial contains whatever it contains, with no independent verification.
All taken on trust: identity, purity, sterility, and the vial's real labeled strength.
The quiet one: a mislabeled concentration breaks all the arithmetic above. The math is only as good as the mg number on the label.
The real worry: that is not a dosing issue, a sourcing issue, and it is the one that would bother us most.
How this page is sourced
No secondary summaries: every figure from the research record above comes straight from the cited papers' abstracts. Not lifted from a secondary summary.
The labels: community numbers are marked as community reports, and the regulatory status was checked live against the FDA, USADA, and ClinicalTrials.gov pages on 19 July 2026.
The six sources: below, with their DOIs and PubMed IDs. Pull them yourself, and hold our numbers up against theirs.
The standard: the sourcing and citation-verification standard for the site lives on the methodology page. Corrections to numbers on this page are made there first.
Last reviewed: 19 July 2026.
-
1
Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625. PMID 42198317.
-
2
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7. PMID 40789979.
-
3
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435.
-
4
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208.
-
5
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8. PMID 30915550.
-
6
Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533. PMID 34267654.
The disclaimer
Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.
It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.
The weekly briefing
Get the next dosage guide.
New compound guides, new calculators, and the math behind the next panic post. One clear email a week.
Education only, never medical advice. Unsubscribe anytime.